Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 amp |
Therapy | Infigratinib + Trametinib |
Indication/Tumor Type | Cancer of Unknown Primary |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 amp | Cancer of Unknown Primary | sensitive | Infigratinib + Trametinib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, the combination of Truseltiq (infigratinib) and Mekinist (trametinib) inhibited Akt and Mapk signaling, induced apoptosis, and synergistically decreased proliferation in FGFR2-amplified cell lines derived from patients with cancer of unknown primary in culture and decreased tumor volume in patient-derived xenograft (PDX) models (PMID: 39033323). | 39033323 |
PubMed Id | Reference Title | Details |
---|---|---|
(39033323) | Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary. | Full reference... |